The Law Offices of Frank R. Cruz Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ: HRMY) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On March 28, 2023, Scorpion Capital published a report alleging, among other things, that Harmony’s narcolepsy drug, Wakix, has “alarming toxicity,” “no efficacy,” is based on “sham patents,” and “scam clinical trials,” and has been “pushed via false advertising and a vast off-label and physician kickback scheme.”

On this news, Harmony’s share price fell $10.70 per share, or 25.8%, to close at $30.80 per share on March 28, 2023, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Harmony securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005959/en/